On August 10, Novo Nordisk and Amazon Web Services (AWS) unveiled a strategic partnership designed to harness the power of artificial intelligence (AI) agents and cloud technology. This collaboration aims to accelerate the drug discovery process and propel the modernization of Novo Nordisk's operational framework. The duo has inaugurated a joint innovation hub in London, with a clear objective to streamline the R&D cycle—spanning from the identification of drug targets to the pivotal first-in-human dosing phase. This move is anticipated to significantly boost R&D efficiency and hasten the introduction of novel therapeutics to the market.